Chartwell Investment Partners, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Chartwell Investment Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	BUY	$83.14 - $145.99 $22,281 - $39,125	268 Added 2.56%	10,741 $1.57 Million
Q1 2022 Apr 26, 2022	BUY	$110.08 - $142.92 $39,518 - $51,308	359 Added 3.55%	10,473 $1.24 Million
Q4 2021 Feb 15, 2022	BUY	$99.73 - $148.48 $229,678 - $341,949	2,303 Added 29.48%	10,114 $1.39 Million
Q3 2021 Nov 16, 2021	SELL	$98.85 - $138.91 $4,052 - $5,695	-41 Reduced 0.52%	7,811 $1.09 Million
Q2 2021 Jul 19, 2021	BUY	$65.78 - $105.02 $1,249 - $1,995	19 Added 0.24%	7,852 $762,000
Q1 2021 May 03, 2021	SELL	$64.07 - $91.75 $14,736 - $21,102	-230 Reduced 2.85%	7,833 $535,000
Q4 2020 Feb 09, 2021	BUY	$65.07 - $98.24 $524,659 - $792,109	8,063 New	8,063 $691,000
Q1 2020 Apr 30, 2020	SELL	$27.51 - $57.29 $559,608 - $1.17 Million	-20,342 Closed	0 $0
Q4 2019 Jan 29, 2020	BUY	$40.86 - $57.65 $831,174 - $1.17 Million	20,342 New	20,342 $1.11 Million
Q4 2017 Feb 08, 2018	SELL	$20.44 - $35.56 $555,232 - $965,951	-27,164 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$23.54 - $38.21 $639,440 - $1.04 Million	27,164	27,164 $1.02 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.